Expanding the Recognition and Assessment of Bleeding Events Associated With Antiplatelet Therapy in Primary Care Marc Cohen, MD Mayo Clinic Proceedings

Slides:

Advertisements

Similar presentations

Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early and long-term clinical outcomes associated.

Advertisements

Date of download: 6/23/2016 Copyright © The American College of Cardiology. All rights reserved. From: A guide to therapeutic decision-making in patients.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Benefit of Early Invasive Therapy in Acute Coronary.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:

Date of download: 7/11/2016 Copyright © The American College of Cardiology. All rights reserved. From: Small molecule glycoprotein IIb/IIIa receptor inhibitors.

From: Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention:

Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial Michael Miller MD,

Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study Dr Jack R W Brownrigg,

Michael J. Koren, MD, Michael H. Davidson, MD, Daniel J

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Diabetes: A Meta-Analysis Stavros Stavrakis, MD The American Journal.

Figure 1 Ischaemic endpoints

Volume 385, Issue 9985, Pages (June 2015)

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

From Inuit to Implementation: Omega-3 Fatty Acids Come of Age

Clinical need for determination of vulnerable plaques

Benefits and risks of using clopidogrel before coronary artery bypass surgery: Systematic review and meta-analysis of randomized trials and observational.

Copyright © 2007 American Medical Association. All rights reserved.

Copyright © 2009 American Medical Association. All rights reserved.

Heart Rate, Life Expectancy and the Cardiovascular System: Therapeutic Considerations Cardiology 2015;132: DOI: / Fig. 1. Semilogarithmic.

Contemporary Diagnosis and Management of Unstable Angina

R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R

Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Chirag Bavishi, MD, MPH,

Masaya Koshizaka, MD, PhD, Renato D. Lopes, MD, PhD, MHS, L

Systolic Blood Pressure Intervention Trial (SPRINT)

Brian Radbill, MD, Barbara Murphy, MD, Derek LeRoith, MD, PhD

Can Vitamin D Deficiency Break Your Heart?

Step Care Therapy for Hypertension in Diabetic Patients

Peripheral Arterial Disease: Diagnosis and Management

Eugene Braunwald, MD, Marc S. Sabatine, MD, MPH

George Dailey, MD Mayo Clinic Proceedings

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Palliative Care and Hospice Programs

George E. Kikano, MD, Marie T. Brown, MD Mayo Clinic Proceedings

Body Composition and Heart Failure Prevalence and Prognosis: Getting to the Fat of the Matter in the “Obesity Paradox” Carl J. Lavie, MD, Richard V.

Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization

Clinical factors associated with long-term mortality following vascular surgery: Outcomes from The Coronary Artery Revascularization Prophylaxis (CARP)

Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study Vasilios Papademetriou, MD, DSc, Eric.

Efficacy and Safety of Thrombin-Receptor Antagonist (Atopaxar and Vorapaxar) in Patients with Acute Coronary Syndrome or Coronary Artery Disease—A Meta-Analysis.

Blood Pressure and Outcomes in Very Old Hypertensive Coronary Artery Disease Patients: An INVEST Substudy Scott J. Denardo, MD, Yan Gong, PhD, Wilmer.

Hazard ratios for the primary end point by subgroup of achieved LDL cholesterol (adjusted for age, sex, baseline calculated LDL cholesterol, diabetes,

Contemporary Evidence-Based Guidelines

To B or Not to B: Is Non–High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B? Carl J. Lavie, MD, Richard V. Milani, MD, James.

Volume 385, Issue 9985, Pages (June 2015)

A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned Robert E.

Peripartum Cardiomyopathy Presenting as an Acute Myocardial Infarction

Risks for Cardiovascular and Cardiac Deaths in Nonobese Patients With Diabetes and Coronary Heart Disease Tetsuro Tsujimoto, MD, PhD, Hiroshi Kajio,

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

MATCH Results: Implications for the Internist

Shannon M. Dunlay, MD, MS, Quinn R. Pack, MD, Randal J

From Inuit to Implementation: Omega-3 Fatty Acids Come of Age

Adjunctive Therapies in the Treatment of Acute Coronary Syndromes

Volume 73, Issue 8, Pages (April 2008)

Strategies for Optimizing Glycemic Control and Cardiovascular Prognosis in Patients With Type 2 Diabetes Mellitus James H. O'Keefe, MD, Mohammad Abuannadi,

Effects of Niacin on Glucose Control in Patients With Dyslipidemia

Medical Treatment of Overactive Bladder: In Response

Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors Barry M. Brenner, Joann Zagrobelny

Marrick L. Kukin, MD Mayo Clinic Proceedings

Coronary Revascularization on Balance: Robert L. Frye Lecture

Michael R. Lattanzio, Matthew R. Weir Kidney International

Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm

Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy? Elias Jabbour, MD, Jorge E. Cortes,

Preoperative Smoking Cessation: The Role of the Primary Care Provider

Volume 75, Issue 1, Pages (January 2009)

Figure 1 Design of trials included in individual patient data meta-analysis. Unless provided in the caption above, the following copyright applies to the.

Guy S. Reeder, M.D. Mayo Clinic Proceedings

Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization

Associations between type of MI and incident HF

Baseline Q Waves and Time From Symptom Onset to ST-segment Elevation Myocardial Infarction: Insights From PLATO on the Influence of Sex Naji Kholaif,

Guy S. Reeder, M.D., Raymond J. Gibbons, M.D. Mayo Clinic Proceedings

R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R

Presentation transcript:

Expanding the Recognition and Assessment of Bleeding Events Associated With Antiplatelet Therapy in Primary Care Marc Cohen, MD Mayo Clinic Proceedings Volume 84, Issue 2, Pages 149-160 (February 2009) DOI: 10.4065/84.2.149 Copyright © 2009 Mayo Foundation for Medical Education and Research Terms and Conditions

FIGURE 1 Kaplan-Meier survival curves for 30-day mortality by severity of bleeding using Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries criteria in an analysis of data from 26,452 patients with acute coronary syndrome participating in 4 randomized controlled trials.21 Log rank P values are P=.20 for mild bleeding vs no bleeding, P<.001 for mild vs moderate bleeding, and P<.001 for moderate vs severe bleeding. Reprinted from Am J Cardiol, 21 with permission from Elsevier, ©2005. Mayo Clinic Proceedings 2009 84, 149-160DOI: (10.4065/84.2.149) Copyright © 2009 Mayo Foundation for Medical Education and Research Terms and Conditions

FIGURE 2 Adjusted hazard ratios (95% confidence intervals) of death or myocardial infarction at 30 days (A) and at 6 months (B) by worsening grade of bleeding using the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) and Thrombolysis in Myocardial Infarction (TIMI) criteria for bleeding severity in a pooled analysis of data from the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy and the Platelet Glycoprotein IIb/IIIa Antagonism for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network studies.25 Separate models were constructed for each grade. Adjustments were made for age, sex, weight, site, diabetes mellitus, smoking status, prior angina, peripheral vascular disease, prerandomization therapy, myocardial infarction at enrollment, systolic and diastolic blood pressure at randomization, heart rate at randomization, Killip class, and assigned treatment. Reprinted from J Am Coll Cardiol,25 with permission from Elsevier, ©2006. Mayo Clinic Proceedings 2009 84, 149-160DOI: (10.4065/84.2.149) Copyright © 2009 Mayo Foundation for Medical Education and Research Terms and Conditions